Description
Cenforce D
Cenforce D is identified by the supplied product name as a combination of sildenafil and dapoxetine. Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction, while dapoxetine is a selective serotonin reuptake inhibitor (SSRI) approved for premature ejaculation in some regions. Combination products have been studied for men who have both erectile dysfunction and premature ejaculation, but this exact trade name should be treated as a product label rather than regulatory proof of approval.
Active Ingredient and Medicine Class
Sildenafil is a PDE5 inhibitor. Dapoxetine is a short-acting SSRI developed for on-demand treatment of premature ejaculation. Regulatory sources describe dapoxetine as the active substance in Priligy and sildenafil as the active substance in widely used erectile dysfunction medicines such as Viagra.
Established Medical Uses
Sildenafil is established for erectile dysfunction, and it is also approved in other formulations for pulmonary arterial hypertension; the erectile dysfunction use is the relevant one for this combination product. Dapoxetine is used for premature ejaculation in adult men in jurisdictions where it is authorised. Published clinical research has evaluated sildenafil/dapoxetine combinations in men with both premature ejaculation and concomitant erectile dysfunction.
How It Works
Sildenafil helps increase blood flow to the penis by enhancing the nitric oxide/cGMP pathway, which supports erection in the presence of sexual stimulation. Dapoxetine increases serotonin signalling by inhibiting serotonin reuptake, which can help delay ejaculation. The combination is intended to address two different mechanisms involved in sexual function.
Important Safety Information
Sildenafil is contraindicated with nitrates and with guanylate cyclase stimulators such as riociguat because of the risk of severe hypotension. It should also be used cautiously in people with cardiovascular disease, low blood pressure, and certain eye or penile conditions. Dapoxetine should not be used with monoamine oxidase inhibitors, thioridazine, or within a short interval of those medicines, and caution is needed with other serotonergic drugs because of serotonin syndrome risk. Both ingredients can contribute to dizziness or faintness, and sildenafil may interact with alpha-blockers and strong CYP3A4 inhibitors.
Possible Side Effects
Common adverse effects reported with sildenafil include headache, flushing, nasal congestion, and dyspepsia; more serious but uncommon reactions include priapism, sudden vision changes, and hearing problems. Dapoxetine is commonly associated with nausea, dizziness, headache, diarrhoea, and insomnia, and less commonly with fainting or other serotonergic adverse effects. In combination studies, reported adverse events were generally mild to moderate, but treatment discontinuation still occurred in some patients.
Scientific Evidence
Evidence from systematic reviews supports dapoxetine as an effective on-demand treatment for premature ejaculation, with modest but meaningful improvements in ejaculation latency and patient-reported outcomes compared with placebo. A clinical study of a dapoxetine/sildenafil combination in men with premature ejaculation and erectile dysfunction found improved latency time and erectile-function scores over a short treatment period, but it was open-label and not definitive. Overall, the combination has some supportive human data, but the evidence base is smaller than for the individual approved uses of each ingredient.
Medical Information Notice
This summary is based on sources available at the time of review and is for educational purposes only. It does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA) – Priligy referral
- DailyMed / FDA label – VIAGRA (sildenafil citrate) tablets, prescribing information
- Salonia et al. – “Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta-analysis” – International Journal of Impotence Research (2016) – PubMed
- Shin et al. – “Efficacy and safety of dapoxetine/sildenafil combination tablets in the treatment of men with premature ejaculation and concomitant erectile dysfunction-DAP-SPEED Study” – International Journal of Impotence Research (2019) – PubMed
